04 Apr 2019

Cancer Transitions — Moving Beyond Treatment

By Anita Shaft

DAVENPORT, IOWA (April 4, 2019) — Gilda’s Club and Genesis Cancer Care Institute are partnering to offer Cancer Transitions™. The workshop begins Tuesday, May 7 (meets for 6 weeks) from 5:30–7:30PM at Gilda’s Club Quad Cities (1234 East River Drive, Davenport, Iowa).

03 Apr 2019

FDA Takes New Steps to Increase Access to Adverse Event Report Data for Medical Products Used in Animals

By David Arvelo

WASHINGTON DC (April 3, 2019) — Today, the US Food and Drug Administration announced it is making available online the adverse event reports related to animal drugs and medical devices used in animals. The reports will go back 30 years.

02 Apr 2019

Amidst Growing Measles Outbreaks, AMA Urges Public to Get Vaccinated

By Kelly Jakubek

CHICAGO, ILLINOIS (April 2, 2019) — In the wake of an announcement by the Centers for Disease Control and Prevention (CDC) that there have been more cases of Measles in the first three months of 2019 than in all of 2018, the American Medical Association (AMA) today issued the following statement urging individuals to check their immunization status and get vaccinated against the measles if not already immune.

02 Apr 2019

FDA Takes New Enforcement Actions as Part of the Agency’s Ongoing Effort to Combat the Illegal Online Sales of Opioids

By David Arvelo

WASHINGTON DC (April 2, 2019) — Today the US Food and Drug Administration announced the issuance of two warning letters to operators of websites that illegally market potentially dangerous, unapproved, and misbranded opioid medications, including tramadol.

02 Apr 2019

FDA Commissioner Scott Gottlieb MD on New Steps to Advance Agency’s Continued Evaluation of Potential Regulatory Pathways for Cannabis-Containing and Cannabis-Derived Products

By David Arvelo

WASHINGTON DC (April 2, 2019) — In recent years, we’ve seen a growing interest in the development of therapies and other FDA-regulated consumer products derived from cannabis (Cannabis sativa L.) and its components, including cannabidiol (CBD). This interest spans the range of product categories that the agency regulates.

02 Apr 2019

Statement from FDA Commissioner Scott Gottlieb MD on the Agency’s Continued Efforts to Bring Competition to the Insulin Market to Lower Prices and Expand Access

By David Arvelo

WASHINGTON DC (April 2, 2019) — Access to affordable insulin can be a matter of life and death for Americans with diabetes. Insulin is a critical hormone that regulates sugar metabolism. The body’s inability to produce sufficient levels of natural insulin can lead to diabetes — both inherited Type 1 and Type 2, typically called adult-onset.

02 Apr 2019

Hy-Vee Providing Free A1C Screenings in April

By Christina Gayman

WEST DES MOINES, IOWA (April 2, 2019) — In honor of National Diabetes Awareness Month, Hy-Vee Inc is providing free Hemoglobin A1C screenings throughout its eight-state region during the month of April.

01 Apr 2019

FDA Warns Homeopathic Firms for Putting Patients at Risk with Significant Violations of Manufacturing Quality Standards

By David Arvelo

WASHINGTON DC (April 1, 2019) — The US Food and Drug Administration (USFDA) today posted warning letters to four companies who produce homeopathic drug-products for significant violations of current good manufacturing practice (CGMP) regulations, including a letter to King Bio Inc of Asheville, NC.

01 Apr 2019

American Medical Association (AMA), Leading Physician Organizations Defend Affordable Care Act Gains in New Texas v United States Court Filing

By American Medical Association

CHICAGO, ILLINOIS (April 1, 2019) — In defense of significant coverage gains and key patient protection provisions of the Affordable Care Act (ACA), the American Medical Association (AMA) and other leading physician organizations today filed an amicus brief in the case of Texas v United States.

30 Mar 2019

FDA Approves New Oral Treatment for Multiple Sclerosis

By David Arvelo

WASHINGTON DC (March 29, 2019) — The US Food and Drug Administration (USDA) today approved Mavenclad (cladribine) tablets to treat relapsing forms of multiple sclerosis (MS) in adults, to include relapsing-remitting disease and active secondary progressive disease. Mavenclad is not recommended for MS patients with clinically-isolated syndrome.

Pages

Subscribe & Listen to Reader Podcasts

On Stands Now

 

Tagged Content

    

Two Ways to Subscribe

1. Subscribe to free weekly e-mail content updates.

You'll get both the current official narrative challenge and What's Happenin' in the Quad Cities.
(Did you know we publish a new Real Astrology and RCR Crossword every week?) 

Subscribe!

* indicates required

2. Get 12 monthly issues mailed first class for $48

Get 12 issues mailed monthly for $48 per year.

Get the printed Reader edition mailed to you (or anyone you want) first-class for 12 months for $48.
$24 goes to postage and handling, $24 goes to keeping the doors open!

Click this link to Subscribe now.